A phase 3 trial is evaluating ASP-1929 photoimmunotherapy plus Keytruda in first-line treatment for recurrent head and neck ...

Nearly 60,000 people are diagnosed with oral cancer in the U.S. every year, according to the American Cancer Society, and the rate of new cases continues to rise.

Nearly 60,000 people are diagnosed with oral cancer in the U.S. every year, according to the American Cancer Society, and the rate of new cases continues to rise. Now, researchers at University of ...

Most head and neck cancers are squamous cell carcinomas that originate from the epithelium of these regions. Accumulating evidence indicates that NUT carcinoma, a highly aggressive malignancy ...

Understanding how tumors change their metabolism to resist treatments is a growing focus in cancer research. As cancer cells adapt to therapies, their metabolism often shifts, which can help them ...

As reported in Biophotonics Discovery, the team developed a novel microscopy technique that uses a standard fluorescence microscope in combination with imaging software. This method allows scientists ...

New Delhi: Drug major Glenmark Pharmaceutical has got the go-ahead from the Subject Expert Committee (SEC) functional under ...

PDS Biotechnology (PDSB) reaffirmed the Company’s guidance of initiating its VERSATILE-003 Phase 3 clinical trial of Versamune HPV plus ...

Initiation of Phase 1/2 combination trial with PYX-201, an extracellular ADC targeting Extradomain-B Fibronectin (EDB+FN) and Merck’s KEYTRUDA® ...